Treatment of Tuberculosis Destructive Joint and Osteomyelitis

Initial Treatment Approach for Drug-Susceptible Disease

The American College of Physicians recommends a standard 6-month four-drug regimen for TB osteoarticular disease, with extension to 9-18 months depending on disease severity, drug resistance patterns, and clinical response 1
The standard regimen composition includes daily isoniazid, rifampin, pyrazinamide, and ethambutol for the first 2 months, followed by isoniazid and rifampin for an additional 4-16 months 1

For isoniazid-resistant disease, the World Health Organization recommends adding a later-generation fluoroquinolone to a 6-month regimen of rifampin, ethambutol, and pyrazinamide 1, 2
Levofloxacin is generally preferred over moxifloxacin due to fewer adverse events and less QTc prolongation 3
For MDR/RR-TB with bone and joint involvement, the European Respiratory Society recommends a longer individualized regimen, including Group A agents such as levofloxacin, bedaquiline, and linezolid 1, 4

The Centers for Disease Control and Prevention advises against adding a single drug to a failing regimen, as this rapidly leads to acquired resistance 1
The European Respiratory Society recommends avoiding kanamycin and capreomycin in MDR-TB regimens due to toxicity without proven benefit 4, 5, 6

No specific guideline society recommendation is provided for surgical intervention criteria, however, surgery is indicated when there is no response after 4-5 months of appropriate chemotherapy, severe cartilage destruction or large abscesses are present, or complications such as pathologic fracture or spinal cord compression occur, as supported by 1